Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2013 Publisher: Rosemont Pharmaceuticals Ltd., Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, LS11 9XE, UK
Pharmacotherapeutic Group: Anti-Parkinson Drugs
ATC Code: N04AB
Orphenadrine, which is a congener of diphenhydramine without sharing its soporific effect, is an anti-muscarinic agent. It also works has weak antihistaminic and local anaesthetic properties.
Orphenadrine is used as the hydrochloride in the symptomatic treatment of Parkinsonism. It is also used to alleviate the extrapyramidal syndrome induced by drugs such as the phenothiazine derivatives, but is of no value in tardive dyskinesia, which may be exacerbated.
Orphenadrine is readily absorbed from the gastro-intestinal tract. It is rapidly distributed in tissues and most of a dose is metabolised to at least 8 metabolites and excreted in the urine along with a small proportion of unchanged drug. A half life of 14 hours has been reported.
Orphenadrine is a drug on which extensive clinical experience has been obtained. Relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
